Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial Results

NEXT STORY
Pulmonary Devices Market Forecast to 2027 – COVID-19 Impact and Global Analysis by Type ; Application ; End User, and Geography
PREV STORY
Verrica Pharmaceuticals Licenses LTX-315, A First-in-Class Oncolytic Peptide Based Immunotherapy, from Lytix Biopharma AS, for the Treatment of Dermatologic Oncology Indications
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Actinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on the Company’s AWE Technology Platform and Research Programs

- Dr. Ludwig brings over 20 years of leadership and management expertise from Eli ...

author_avatar
NASDAQ Market News

Conduent Market-Leading Disease Surveillance and Outbreak Management System to Fight Coronavirus

author_avatar
NASDAQ Market News

Hemispherx Reports Positive Safety and Survival Data in Phase 1 Stage 4 Ovarian Cancer Clinical Study Using Ampligen®

author_avatar
NASDAQ Market News